Gene therapeutic approaches to primary and metastatic brain tumors: II. Ribozyme-mediated suppression of CD44 expression
- 1 December 1995
- journal article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 26 (3) , 251-257
- https://doi.org/10.1007/bf01052628
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Expression of CD44 splice variants in human primary brain tumorsJournal of Neuro-Oncology, 1995
- Expression of variant CD44 epitopes in human astrocytic brain tumorsJournal of Neuro-Oncology, 1995
- Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras geneGene, 1992
- SMALL CATALYTIC RNAsAnnual Review of Biochemistry, 1992
- Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein.Proceedings of the National Academy of Sciences, 1991
- Molecular cloning of CD44R1 and CD44R2, two novel isoforms of the human CD44 lymphocyte "homing" receptor expressed by hemopoietic cells.The Journal of Experimental Medicine, 1991
- Ribozymes as Potential Anti-HIV-1 Therapeutic AgentsScience, 1990
- Simple RNA enzymes with new and highly specific endoribonuclease activitiesNature, 1988
- A small catalytic oligoribonucleotideNature, 1987
- Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sitesCell, 1987